64
Participants
Start Date
August 8, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
July 31, 2025
MBX 2109
Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
Placebo
Supplied in 1.4 mL water for injection
MBX Biosciences Investigational Site, Great Neck
MBX Biosciences Investigational Site, New York
MBX Biosciences Investigational Site, The Bronx
MBX Biosciences Investigational Site, Albany
MBX Biosciences Investigational Site, Philadelphia
MBX Biosciences Investigational Site, Greenville
MBX Biosciences Investigational Site, Macon
MBX Biosciences Investigational Site, Jacksonville
MBX Biosciences Investigational Site, Jacksonville
MBX Biosciences Investigational Site, Miami
MBX Biosciences Investigational Site, Jackson
MBX Biosciences Investigational Site, Columbus
MBX Biosciences Investigational Site, Cleveland
MBX Biosciences Investigational Site, Madison
MBX Biosciences Investigational Site, Chicago
MBX Biosciences Investigational Site, Chicago
MBX Biosciences Investigational Site, St Louis
MBX Biosciences Investigational Site, Omaha
MBX Biosciences Investigational Site, Dallas
MBX Biosciences Investigational Site, Fort Worth
MBX Biosciences Investigational Site, San Antonio
MBX Biosciences Investigational Site, Weslaco
MBX Biosciences Investigational Site, Round Rock
MBX Biosciences Investigational Site, El Paso
MBX Biosciences Investigational Site, Las Vegas
MBX Biosciences Investigational Site, Reno
MBX Biosciences Investigational Site, Sacramento
MBX Biosciences Investigational Site, CABA
MBX Biosciences Investigational Site, CABA
Lead Sponsor
MBX Biosciences
INDUSTRY